Key facts
- This page summarizes Kevin J. Ballinger's Form 4 filing for Silk Road Medical Inc.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Sep 2024, 20:48.
Kevin J. Ballinger - 17 Sep 2024 Form 4 Insider Report for Silk Road Medical Inc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 17 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 Sep 2024, 20:48:35 UTC
- Prior SEC filing
- 05 Sep 2024
- Next SEC filing
- 05 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mhairi Jones, by power of attorney
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kevin J. Ballinger filed Form 4 for Silk Road Medical Inc on 18 Sep 2024.
Change
- Previous filing in this sequence was filed on 05 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SILK
transaction
Common Stock
Disposed to Issuer
- Transaction value
- Shares
- -23,666
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 17 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Kevin J. Ballinger is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 3 footnotes
Footnote F1
Of the reported shares, 5,859 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.
Footnote F2
Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.
Footnote F3
Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.